The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised 2018 evidence-based guideline, “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors.”
Opinion | Diversity Action Plans for Clinical Trials: Evaluating FDA’s Draft Guidance
Lazarus is an adjunct professor of psychiatry. Jernigan is chief operating officer of a service provider for participants in clinical trials. The FDA is intent